Abstract | BACKGROUND AND OBJECTIVES: DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: A systematic review of the literature (Medline, EMBASE, Cochrane CENTRAL and Google Scholar databases) was done to determine the bleeding risk in ESRD patients prescribed antiplatelet therapy. The secondary outcome was the effect on access thrombosis. All case series, cohort studies and clinical trials were considered if they included ten or more ESRD patients, assessed bleeding risk with antiplatelet agents, and lasted for more than 3 mo. RESULTS: CONCLUSION: The risks and benefits of antiplatelet agents in ESRD patients remain poorly defined. Until a clinical trial addresses this in the dialysis population, individual risk stratification taking into account the increased risk of bleeding should be considered before initiating antiplatelet agents, especially in combination therapy.
|
Authors | Swapnil Hiremath, Rachel M Holden, Dean Fergusson, Deborah L Zimmerman |
Journal | Clinical journal of the American Society of Nephrology : CJASN
(Clin J Am Soc Nephrol)
Vol. 4
Issue 8
Pg. 1347-55
(Aug 2009)
ISSN: 1555-905X [Electronic] United States |
PMID | 19578002
(Publication Type: Journal Article, Review, Systematic Review)
|
Chemical References |
- Platelet Aggregation Inhibitors
|
Topics |
- Arteriovenous Shunt, Surgical
(adverse effects)
- Blood Vessel Prosthesis Implantation
(adverse effects)
- Catheterization, Central Venous
(adverse effects)
- Drug Therapy, Combination
- Hemorrhage
(chemically induced)
- Humans
- Kidney Failure, Chronic
(blood, drug therapy, therapy)
- Platelet Aggregation Inhibitors
(adverse effects)
- Renal Dialysis
(adverse effects)
- Risk Assessment
- Thrombosis
(etiology, prevention & control)
- Treatment Outcome
|